# Cannabidiol for Reduction of Brain Neuroinflammation

> **NCT05066308** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Back Pain
- Depressive Symptoms

## Interventions

- **DRUG:** CBD
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05066308
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-04
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066308, "Cannabidiol for Reduction of Brain Neuroinflammation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05066308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*